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ABSTRACT 
A simple, precise and accurate RP-HPLC method has been developed and subsequently 
validated for simultaneous estimation of Aliskiren Hemifumarate and Nicardipine Besylate 
from their combination dosage form. Aliskiren and Nicardipine  are widely used 
antihypertensive drugs at present but their analytical methods are very costly & very complex 
to simplify the methods with increasing sensitivity new methods were developed which are 
simple, precise, eco-friendly, less time consuming, rapid & fast & economically chief. First 
standard curve was plotted then the method is validated by using recovery studies, linearity, 
correctness & reproducibility, robustness, ruggedness, detection limit,  quantification limits, 
stability studies etc.  The validated technique has been with success used for stress testing 
analysis of Aliskiren & Nicardipine. The stress testing studies revealed that the tactic was 
with success utilized to resolve the degraded product from the sample. From the peak purity 
profile it had been demonstrated that there was no interference of degradation product & the 
purity of angle were found to be but the purity of threshold. This work was undertaken with 
an aim of developing HPLC and Specrophotometric techniques for analysis of Aliskiren and 
Nicardipine. Number of trials was taken for selection of column & M. Phase’. The proposed 
method was validated as per the ICH and USP guidelines.  
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INTRODUCTION 
Aliskiren is a novel antihypertensive agent & is that the 1st orally active enzyme substance 
indicated for the treatment of cardiovascular disease. Chemically, Aliskiren is 
(2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2- methylpropyl)-5-amino-4 hydroxy2,7 diisopropyl -8-
[4- methoxy-3-(3-methoxypropoxy)phenyl] octanamide hemifumarate)(Figure 1)
1, 2, 3
. The 
first oral direct renin inhibitor approved for clinical use, exhibits a novel and advantageous 
pharmacokinetic and pharmacodynamic profile for the long-term treatment of hypertension. 
Aliskiren blocks the renin system at its rate-limiting step by directly inhibiting the catalytic 
activity of renin, thereby reducing generation of angiotensin I and angiotensin II. Aliskiren 
represents the first in a novel class of renin inhibitors with the potential for treatment of 
hypertension and related cardiovascular diseases
.4
 
Nicardipine is a member of 1, 4-dihydropyridine class of metal antagonist approved for the 
treatment of heart diseases like cardiovascular disease & angina pectoris. It is a 
protracted acting metal channel blocker that inhibits the flow of calcium ions into 
the tube swish muscle & muscular tissue with chemicals Nicardipine is 3-ethyl-5-methyl 2 
[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydropyridine-6-methyl-
3,5dicarboxylate(Figure 2). 
Through literature survey reveals that there square measure few analytical ways such as RP-
HPLC & ultraviolet light ways are rumored for synchronous estimation of Aliskiren & 
Nicardipine in pharmaceutical dose forms. But therefore way there's no stability indicating 
technique rumored. Therefore the gift investigation was allotted to develop new easy, precise, 
rapid, & cost-effective stability indicating RP-HPLC technique for the synchronous 
estimation of Aliskiren & Nicardipine in pharmaceutical dose kind. Present work emphasizes 
on the quantitative estimation of Aliskiren and Nicardipine in their combined dosage form 
(Tablets) by RP-HPLC. The proposed technique was also successfully used to separate the 
degraded product from the samples. 
 MATERIALS AND METHODS 
Aliskiren & Nicardipine standards were provided from Spectrum Research Laboratory, 
Hyderabad, & commercial pill dose kind TEKEMLO was purchased from native market. The 
HPLC grade acetonitrile & water were purchased from Merck & analytical grade potassium 
dihydrogen phosphate was purchased from RANKEM. Analytical grade triethylamine, 
orthophosphoric acid, hydrochloric acid, sodium hydroxide, & hydrogen peroxide were 
purchased from S.D. Fine Chemicals. 
Preparation of buffer resolution for mobile phase-A: 
Dissolved 1.36 gram metal diatomic number 1 ortho phosphate into 1L of HPLC grade water. 
Mixed well using a magnetic stirrer bar till fully mixed. The solution was filtered through 
a zerom nylon membrane filter 45 & degassed. 
Preparation of mobile Phase-B: Acetonitrile (HPLC Grade) 
Preparation of diluents: fuel (HPLC Grade) 
Intact pills of Aliskiren Hemifumarate & Nicardipine Besylate taken into 500 ml volumetric 
flask than additional 10 ml of water & sonicated until disintegrated. Added concerning 400 
ml of fuel & sonicated for 45 minutes than created up volume with fuel. Added 5 ml of this 
resolution in to 50 mm volumetric flask & build up volume with fuel & filtered with 0.45 µm 
nylon filter. A Validated Stability Indicating RP-HPLC technique Development & Validation 
for synchronous Estimation of Aliskiren Hemifumarate & Nicardipine Besylate in 
Pharmaceutical dose kind. The present study describes the soundness indicating RP-HPLC 
technique for synchronous estimation of Aliskiren hemifumarate & Nicardipine besylate in 
pharmaceutical dose forms.  
HPLC Instrument: 
The chromatographic separation was carried out by waters 2695 HPLC system separation 
module (Labtronic) equipped with personal digital assistant detector & autosampler. The 
Empower 2 package was used for signal observation & process. UV chamber has been used 
for photolytic degradation & hot air kitchen appliance was utilized for thermal degradation. 
Conditions of Chromatography 
The chromatographic separation of analytes was carried out exploitation Labtronics RP-
HPLC system with C-18 hypersil ODS (150 × four.6 mm, 5 μm) column. The mobile phase 
consists of phosphate buffer & acetonitrile in the ration of 40 : 60% v/v & hydrogen ion 
concentration was adjusted to three with phosphoric acid resolution that was wont to separate 
the analytes & column temperature was maintained at 30°C. The analytes were detected at 
237 nm using personal digital assistant detector. The run time was set at 10 min at a flow rate 
of 1 mL/min.5,6 Data are provided in table 1. 
Standard stock solution preparation 
Standard stock solutions of aliskiren & Nicardipine were prepared individually by dissolving 
50 mg of Aliskiren & 10 mg of Nicardipine in 10 mL volumetrical flasks with 
water : acetonitrile (50 : 50% v/v) as dilutant & sonicated for 5 min. From the above 
resolution transfer 0.3 mL of Aliskiren & 0.1 mL of Nicardipine separately into 10 mL 
volumetrical flasks & build up the amount with dilutant to induce 150 μg/mL of Aliskiren & 
10 μg/mL of Nicardipine standard stock resolution. 
Sample solution Preparation 
Five pills (TAKEMLO tablets: 150 mg Aliskiren & 10 mg Nicardipine) were weighed & the 
average weight of every tablet was calculated; then the load such as 5 tablets was transferred 
into a 250 mL volumetrical flask; 60 mL of dilutant was additional & sonicated for 25 min; 
and the amount was created up with dilutant & filtered. From the filtered solution 0.5 mL was 
pipetted out into a 10 mL volumetric flask & created up to 10 mL with dilutant. 
Degradation studies by Force
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 Forced degradation studies of the drug formulation were carried out by treating the drug 
samples under stress evoked conditions like acid & base chemical reaction, oxidation, & 
photo & thermal degradation & interference of the degraded products was investigated. These 
studies help to understand the inherent stability characteristic of the active molecules in drug 
product & the attainable degradation product  
Degradation studies by acid
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To 1 mL stock solution of Aliskiren & Nicardipine, 1 mL of 2N hydrochloric acid was added 
& refluxed for 30 mins at 60°C. The resultant resolution was diluted to get 150 μg/mL & 
10 μg/mL solution & 10 μL solutions were injected into the system & the chromatograms 
were recorded to assess the soundness of sample. 
Degradation studies by acid
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To 1 mL stock solution of aliskiren & Nicardipine, 1 mL of 2N sodium hydroxide was 
additional & refluxed for 30 min at 60°C. The sample resolution was ready to get the 
concentration of 150 μg/mL & 10 μg/mL solution & 10 μL was injected into the system & the 
chromatograms were recorded to assess the soundness of sample. 
Oxidation
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To 1 mL stock solution of aliskiren & Nicardipine, 1 mL of 20% atomic number 1 peroxide 
(H2O2) was additional individually. The solutions were kept for 30 min at 60°C. For HPLC 
study, the sample resolution was ready to get the concentration of 150 μg/mL & 10 μg/mL 
solution & 10 μL was injected into the system & the chromatograms were recorded to assess 
the soundness of sample. 
Photo stability studies
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The photochemical stability of the drug was conjointly studied by exposing the 150 μg/mL & 
10 μg/mL resolution to light-weight|ultraviolet illumination|UV|actinic radiation|actinic ray} 
light by keeping the beaker in ultraviolet light chamber for seven days or two hundred watt 
hours/m2 in photo stability chamber. For HPLC study, the sample resolution was ready to get 
the concentration of 150 μg/mL & 10 μg/mL solution & 10 μL was injected into the system & 
the chromatograms were recorded to assess the soundness of sample. 
Degradation studies by Dry Heat
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The standard drug solution was placed in kitchen appliance at 105°C for 6 h to study dry heat 
degradation. For HPLC study, the sample resolution was ready to get the concentration of 
150 μg/mL & 10 μg/mL solution & 10 μL was injected into the system & the chromatograms 
were recorded to assess the soundness of the sample. 
RESULT & DISCUSSION 
A series of trials was conducted with completely different columns like Inertsil ODS & 
agilent XDB C-18 & C-8 columns with different mobile phases to develop a appropriate RP-
HPLC technique for estimation of Aliskiren hemifumarate & Nicardipine besylate in pill 
dose kind, & finally a typical chromatogram was obtained with phosphate buffer & 
acetonitrile in the ration of 40 : 60% v/v & hydrogen ion concentration was adjusted to 
three with phosphoric acid at a rate of 1 mL/min. The chromatographic separation was 
performed on C-8 Inertsil ODS (150 × 4.6 mm, 5 μ) by injecting 10 μL & analytes were 
detected with PDA detector at 237 nm. The retention time of Aliskiren & Nicardipine was 
found to be 3.98 & 5.14 min respectively. Forced degradation studies were also carried 
exploitation the developed technique & the degraded compounds were effectively resolved 
from the Aliskiren & Nicardipine in pill dose kind.  
Method Validation 
The validation was performed with above developed RP HPLC technique for synchronous 
estimation of Aliskiren & Nicardipine according to ICH tips. Various parameters were 
evaluated such as system quality, precision, accuracy, linearity, robustness, LOD, & LOQ 
System Suitability Parameters 
 System suitability was performed to verify the acceptableness of the resolution & 
repeatability of the system. System suitability was performed by injecting six replicate 
injections of the standard resolution (100%) & parameters such as peak space, USP tailing, 
theoretical plates, retention time, & peak asymmetry were evaluated. The % RSD determined 
and rumored inside the bounds.   
Accuracy 
The accuracy of the proposed technique was evaluated by calculating the recovery studies of 
drug at 3 completely different concentration levels (50%, 100%, & 150%) by standard 
addition method. A known quantity of Aliskiren & Nicardipine was additional to pre-
quantified sample resolution & 3 replicates of every concentration were injected in developed 
chromatographical conditions. The mean percentage recovery of Aliskiren & Nicardipine was 
varied between 99.99 & 101.7% indicating that the developed technique was found to 
be correct.  
The precision of Associate in nursing analytical procedure could be outlined because the 
closeness of agreement between a series of measurements obtained from multiple sampling 
of an equivalent solid sample underneath the prescribed conditions. The method exactitude & 
system exactitude studies were allotted by injecting 6 replicates of each standard & take a 
look at solutions with an equivalent concentration. The % RSD was calculated from the 
chromatograms & results obtained were inside the bounds of 22 & planned technique was 
found to be precise. 
Precision 
The linearity of the technique determined at completely different concentration levels starting 
from 30 to 55 μg/mL of Aliskiren & from 2 to 15 μg/mL of Nicardipine. All the 
concentrations were prepared & injected into the system. The linearity curve was created by 
plotting peak space versus concentration of the analyte. From the results obtained the 
proposed technique was found to be linear. The regression coefficient was found to be 0.9990 
for both Aliskiren & Nicardipine (Figure 3, and 4). 
Lim. of Detection & Quantification (LOD & LOQ) 
In the present study the LOD & LOQ of Aliskiren & Nicardipine were 
evaluated supported the standard activity curve technique. Limit of detection is performed to 
know the bottom concentration level of the analytes that provides measurable response. The 
LOD was found to be 0.1614 μg/mL & 0.1336 μg/mL & LOQ was 0.4890 μg/mL & 
0.4049 μg/mL for Aliskiren & Nicardipine respectively. Data are provided in table 2. 
Robustness 
Robustness of the planned technique has been evaluated by tiny deliberate changes in the 
system parameters like rate, mobile phase composition, pH of the mobile part, & temperature. 
It was found that none of the above parameters caused alteration within the peak space, 
retention time, & USP tailing by small changes like ±0.1 mL change in flow rate, ±5% 
change in mobile part, & ±5°C change in temperature. The % RSD was found to be inside the 
bounds & the tactic was found to be sturdy.  
Assay 
Analysis of marketed formulation (TAKEMLO tablets, 150 mg Aliskiren & 10 mg of 
Nicardipine, Novartis, Mumbai, India) was purchased from local market. Five tablets were 
weighed & average weight was calculated; weight equivalent to five tablets was transferred 
into a 250 mL volumetrical flask, 60 mL of diluent was additional & sonicated for 25 min, & 
further the volume was created up with dilutant & filtered. From the filtered solution 0.5 mL 
was pipetted out into a 10 mL volumetric flask & created up to 10 mL with dilutant. From the 
resulting resolution 10 μL was injected into HPLC system & peak areas were recorded. The 
% assay of the marketed formulation was found to be 99.15% for Aliskiren & 99.87% for 
Nicardipine  
 Force Degradation Studies 
In the present study forced degradation studies were allotted to make sure the effective 
separation of Aliskiren & Nicardipine from degradation product. Degradation was observed 
by decreasing the peak areas of the drug substances with same drug molecules of degraded 
peak areas. The percentage assay of degradation was calculated from the height space 
obtained in degradation conditions & it had been compared with assay of non-degraded 
conditions. Acidic & alkali degradation was carried out by treating the sample solution with 
2N HCl & 2N NaOH solutions. From the chromatograms, it was found that each the 
molecules square measure prone to acidic & alkali degradation & proportion assay 
degradation in both acidic & alkali conditions was found to be inside the bounds. Oxidative 
degradation studies were performed by treating two hundredth H2O2 resolution & keeping it 
at 60°C for 30 min. The results showed that there was no degradation products shaped. For 
thermal stress studies the drug solutions were placed in oven at 105°C for 6 h & then injected 
into HPLC system & photo stress testing was carried out by keeping the drug solutions 
in ultraviolet light chamber for seven days. In all the conditions the purity of angle is found to 
be but that of purity of threshold which indicates that the developed technique was stability 
indicating. The forced degradation studies were performed without intending to establish the 
degradation product however just to point out that they are not officious with active 
molecules if any gift.  
CONCLUSION: 
In the present study, a stability indicating RP-HPLC method has been developed & valid for 
synchronous estimation of Aliskiren & Nicardipine in pill dose kind. The validated technique 
has been with success used for stress testing analysis of aliskiren & Nicardipine. The stress 
testing studies revealed that the tactic was with success utilized to resolve the degraded 
product from the sample. From the peak purity profile it had been demonstrated that there 
was no interference of degradation product & the purity of angle were found to be but the 
purity of threshold. The proposed technique was tested to be selective, accurate, precise, & 
rapid & it can successfully used for routine analysis of Aliskiren hemifumarate and 
Nicardipine in bulk and tablet dosage formulation. The method can also be employed in 
quality control of pharmaceuticals containing Aliskiren and Nicardipine to reduce analytical 
time. 
ACKNOWLEDGEMENTS: 
The authors are thankful to management of Institute of pharmacy, Shri Jagdish Prasad 
Jhabarmal Tibrewala University for their kind help and providing all necessary facilities and 
also thankful to Novartis, Mumbai, India for providing tablets for this research work. 
CONFLICT OF INTEREST:  
Authors declares that there is no conflict of interest 
 
 
REFERENCES: 
1. Available from: http//www.rx list.com/Aliskiren/ Valsartan.  
2. The Merck Index, 14th edition, Merck and Co, 2006. Monographs 3521, 3535. 
3. Kumaraswamy G, Kumar JMR , Sheshagiri Rao JVLN, Lakshmi Surekha M, Validated 
RP-HPLC method for simultaneous estimation of aliskiren and valsartan in tablet dosage 
form. Journal of Drug Delivery & Therapeutics; 2012, 2(5):162-166 
4. Shah J, Parmar K, Development & validation of HPLC method for analysis of some an-
tihypertensive agents in their pharmaceutical dosage forms, Journal of Drug Delivery & 
Therapeutics; 2014, 4(2):12-15. 
 5. Shreevastav A., Gupta V. B., Stabilities showing R. P. -H. P. L. C. procedures for the 
simultan. Determinat
n
 of Prajosin, Terajosin, & Doxazosine in pharma preparations, Sci 
pharm., 2012; 80:619-631. 
6. Prashad C.V. N. , Gautam A. , Bhardawaj V. , Paraimoo P., Quantitatively determinatn of 
Terasosin Hydrochloride in tab. Preparat
n
 by fluorimetric analysis. Indian Journal 
Pharmaceutical Science. 1998; 60:167-169.  
7. International Conference on Harmonization (ICH), Validation of Analytical Procedures: 
Methodology Q2B, 1996. 
8. Mendham J., Denny R.C., Barnes J.D., Thomas M.J.K., Vogel’s, Text book of 
Quantitative Chemical Analysis, 6
th
 edition, Pearson Education Pvt. Ltd., New Delhi, 
2002, 261-263,268,277,653,654. 
9. Snyder R.I., Kirkland J.J., Glajch J.L., Practical HPLC Method development, Published 
By John Wiley and Son, Inc, New York, 2ndEdn., 1997, pp.21-57. 
10. International Conference on Harmonization (ICH), Validation of Analytical Procedures: 
Text and Methodology Q2 (R1), 2005. 
 
TABLES AND FIGURES 
CH3
CH3
O
CH3
O O
CH3
H
CH3
CH3
NH2
OH
H
NH
CH3
O
CH3
NH2O
 
Figure 1: Chemical structure of Aliskiren 
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Figure 2: Chemical structure of Nicardipine 
 
Figure 3: Calibration graph for Aliskiren. 
  
Figure 4: Calibration graph for Nicardipine 
Table 1: Conditions of Chromatography 
Column C-18 hypersil ODS (150 × four.6 mm, 5 μm) 
Sample temperature 30°C 
Injection volume 10 µL 
Flow rate 1 mL/min 
Detector wavelength 237nm 
Column temperature 30°C 
Detector UV 
Diluent BUFFER:ACN (40:60) 
Mobile phase B Acetonitrile 
Mobile phase A phosphate buffer 
Run time 10 mins. 
 
Table 2: System suitability parameters 
Parameter Result (Aliskiren) Result (Nicardipine) 
Linearity (μg/ml)  30–225  2–15  
Correlation coefficient 0.9990 0.9990 
LOD (μg/ml) 0.1614 μg/mL   0.1336 μg/mL 
LOQ(μg/ml) 0.4890 μg/mL  0.4049 μg/mL 
 
